VENMAX DRUGS AND PHARMACEUTICALS LIMITED.

May 15, 2026

To,
BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.

Scrip Code: 531015

Sub: Statement of deviation or variation in the use of proceeds raised through Preferential Issue

Dear Sir/Madam,

Pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that there is no deviation or variation in the use of proceeds raised through Preferential Issue from the objects stated in the EGM Notice for Preferential Issue. A statement confirming that there is no deviation or variation in the utilization of these proceeds for the quarter and Year ended March 31, 2026, duly reviewed by the Audit Committee in the meeting held on 14.05.2026, is enclosed herewith as "Annexure A".

Kindly take the above information on record and oblige.

Thanking You

Yours Faithfully

For Venmax Drugs & Pharmaceuticals Limited

Sadhanala Venkata Rao
Digitally signed by Sadhanala Venkata Rao
Date: 2026.05.15 14:01:31 +05'30'

Venkata Rao Sadhanala
Managing Director
DIN: 02906370

Reg Office: Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad – 500009
CIN: L24230TG1988PLC009102 GSTIN: 36AAACY1073C3ZM

E-mail: venmaxdrugs@gmail.com

VENMAX
DRUGS AND PHARMACEUTICALS LIMITED.

Statement of Deviation / Variation in utilization of funds raised:

Annexure A

Name of listed entity	Venmax Drugs and Pharmaceuticals Limited
Mode of Fund Raising	Issue of Fully Convertible Equity Warrants on Preferential Basis
Date of Raising Funds	March 20, 2025
Amount Raised	Rs. 20.05 crores to be raised in total, out of which 1. Rs. 12.69 crores have been raised and received from investors against 63,44,000 conversions of share warrants. 2. 1.84 crores received against 36,81,000 share warrants.
Report filed for Quarter ended	March 31, 2026
Monitoring Agency	NA
Monitoring Agency Name, if applicable	NA
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	February 6, 2025
Explanation for the Deviation /Variation	Not Applicable
Comments of the Audit Committee after review	NA
Comments of the auditors, if any	Nil

Reg Office: Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad – 500009
CIN: L24230TG1988PLC009102 GSTIN: 36AAACY1073C3ZM

E-mail: venmaxdrugs@gmail.com

Objects for which funds have been raised:

Original Object	Modified Object, if any	Original Allocation	Revised Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation /Variation for the quarter according to applicable object	Remarks if any
1. Working Capital	Not Applicable	Rs. 10 crores	Not Applicable	Not Applicable	Till 31st March 2026, Rs. 8.12 crores was utilized.	Not Applicable	No Deviation
2. General Corporate Purpose and Business Acquisition	Not Applicable	Rs. 10.05 crores	Not Applicable	Not Applicable	Till 31st March 2026, Rs. 0.20 crores was utilized.	Not Applicable	No Deviation

For Venmax Drugs & Pharmaceuticals Limited

Sadhanala Venkata Rao

Digitally signed by Sadhanala Venkata Rao
Date: 2026.05.15 14:02:06 +05'30'

Venkata Rao Sadhanala
Managing Director
DIN: 02906370